CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Exenatide +1 moredrug
Likely dose
Exenatide 5 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02160990
NCT02160990Phase 4Completed
CompareCT.gov

Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying

Mayo Clinic·interventional·Posted Jun 11, 2014·Updated Aug 9, 2016

In Brief

A Phase 4 clinical trial evaluating Exenatide and Placebo for Obesity. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The overall goal of this study was to determine the effect of exenatide on gastric emptying, satiety and satiation in obese participants. The hypothesis in this study was that exenatide retards gastric emptying in obese patients with baseline accelerated gastric emptying.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 11, 2014
Enrollment StartJun 1, 2014
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.1 years ago

Interventions

Exenatidedrug

5 mcg exenatide subcutaneously twice daily for 30 days

Placebodrug

placebo subcutaneously twice daily for 30 days